No abstract

Commercial layer hens reared on multi-age hen complexes are vaccinated during pullet rearing to combat production losses due to the bacteria Mycoplasma gallisepticum (MG). In this study, the potential to in ovo vaccinate layer chickens against MG was investigated. Layer embryos were administered a dosage of a live attenuated strain F MG (FMG) vaccine at 18 d of incubation and raised for 6 wk for initial post-hatch evaluation in 2 replicate trials. Treatments included control non-injected eggs, eggs injected with diluent, a non-diluted dosage, a 10-2 dilution, a 10-4 dilution, and a 10-6 dilution. A subset of chicks were swabbed for detection of FMG in the trachea at hatch. At 6 wk of age, birds were swabbed again for FMG detection and a blood sample was tested for MG antibody production. Hatch was depressed in the non-diluted dose group (P < 0.0001). Strain F MG was detected at hatch in the trachea in each FMG injection treatment, with decreasing numbers of positive chicks in the lower dosage groups. Mortality during the first 2 wk post-hatch was 3.5% (trial 1) and was 11.7% (trial 2) in the 10-6 dilution treatment, with all other FMG treatments experiencing a high rate of mortality (>50%). Birds in the in ovo FMG treatments had detectable FMG and antibody production at 6 wk. There were no differences in percentage positive birds (P > 0.3 for all tests) or ELISA titers (P = 0.079) between the FMG treatments. Body weight at 6 wk of age was diminished with increasing FMG dose (P < 0.0001). The lowest dose tested was found to be the most practical, causing the least mortality, least weight loss, and a humoral immune response in the majority of the birds. Further work is needed to evaluate how this in ovo vaccine, promoting immunity earlier, would compare to a standard post-hatch vaccination against an MG challenge scenario through a lay cycle.

The effects of in ovo injected vitamin D 3 source on eggshell temperature ( ET ) and performance of broilers through 14 D of age ( doa ) were investigated. Eggs from a 35-wk-old commercial Ross 708 broiler breeder flock were set in a single-stage incubator with 4 treatments representing each of 12 incubator tray levels (blocks). At 432 h of incubation ( hoi ), noninjected and diluent-injected (50 μL) groups were control treatment groups. Vitamin treatments in the commercial diluent were as follows: 2.4 μg of vitamin D 3 ( D 3 ) or 25-hydroxylcholecalciferol ( 25OHD 3 ). After injection, ET readings were recorded (435, 441, 453, 459, and 465 hoi) by infrared thermometry. Hatchability, hatchling BW, and percentage of male and female hatchlings were determined at 502 hoi. Equal numbers of male and female chicks were placed in each pen and grown out for 14 doa. On a per-pen basis, BW was recorded after hatching at day 7 and 14 doa, and BW gain, average daily BW gain, feed intake ( FI ), and feed conversion ratio ( FCR ) were calculated between 0 to 14 doa. The ET of eggs significantly fluctuated during the postinjection time period; however, the type of vitamin D 3 source injected did not affect ET. Nevertheless, the injection of 25OHD 3 resulted in a lower late embryo mortality than the diluent and D 3 injection treatments. In addition, birds that received 25OHD 3 had a lower FI and FCR than birds in all other treatments. In conclusion, the in ovo injection of 25OHD 3 has the potential to improve early posthatch broiler performance without affecting ET.

Mycoplasma gallisepticum (MG) is a bacterial pathogen that causes production losses in layer chickens. To combat MG, multiage layer facilities vaccinate pullets by either spray or eye-drop vaccination. The objective in this study was to evaluate the use of in ovo vaccination as a potential alternative for MG vaccination. Layer embryos at 18 d of incubation were either not-injected (control), or were hand-injected with either commercial Marek's disease vaccine diluent alone or with a high, medium, low, or very low dosage of a live attenuated strain F (FMG) vaccine suspended in the commercial diluent. Hatch success and residual egg embryonic mortality were determined after 23 d of incubation. Six hatched chicks per treatment were swabbed for the detection of FMG at 4 different sites (trachea, mouth and esophagus, yolk sac membrane, and the lumen of the duodenal loop) via real-time PCR. Embryos were found to be administered 106 CFU per dose in the high treatment, 104 CFU/dose in the medium treatment, 102 CFU/dose in the low treatment, and between 5.06 and 5.93 CFU/dose in the very low treatment. Hatch of embryonated eggs was decreased by the medium and high doses (P = 0.02). These embryos died while pipping. No FMG was detected in the control and diluent-injected chicks. In the FMG treatments, FMG was found in all sites and dosages, with a greater number of positive chicks found in the higher FMG dosage treatments. These findings indicate the potential practicality of vaccinating layer embryos with FMG by in ovo injection based on the observed hatch success at lower dosages. Also, once injected into the amnion, the bacteria are present in the upper respiratory and gastrointestinal tracts as well the yolk sac membrane and the small intestine of hatchlings. Future research will need to ascertain the effects of FMG administered by in ovo injection on posthatch immunity and mortality.

The effects of the in ovo administration of vitamin D 3 ( D 3 ) and its metabolite, 25-hydroxyvitamin D 3 ( 25OHD 3 ) , on the performance, breast meat yield, and inflammatory responses of broilers fed commercial diets were investigated. Live embryonated Ross 708 broiler hatching eggs were randomly assigned to one of the following 5 in ovo injection treatments at 18 d of incubation: 1) noninjected; 2) diluent; diluent containing 3) 2.4-μg D 3 , 4) 2.4-μg 25OHD 3 , or 5) 2.4-μg D 3 + 2.4-μg 25OHD 3 . A 50-μL solution volume of each prespecified treatment was injected into each egg using an Inovoject multiegg injector. At hatch, 18 male chicks were randomly assigned to each of 30 floor pens. The BW, BW gain, feed intake, and feed conversion ratio of the birds were determined in each dietary phase. At 14, 28, and 39 d of posthatch age ( doa ), plasma α-1-acid glycoprotein ( AGP ) levels in 1 bird in each of 6 replicate pens per treatment were determined at 14 and 39 doa. The pectoralis major and minor weights of those same birds were also determined. The remaining birds were processed at 43 doa, and the weights of their processing parts were determined. At 39 doa, the in ovo injection of 25OHD 3 alone decreased plasma AGP concentrations in comparison with the noninjected, diluent, and D 3 -alone treatment groups. In addition, birds that received 25OHD 3 alone had a greater BW at 42 doa than birds in the noninjected, diluent, and D 3 -alone treatment groups. At 39 and 43 doa, breast meat yield was increased in response to the in ovo injection of 25OHD 3 alone in comparison to all other treatments. These results indicate that the in ovo injection of 2.4 μg of 25OHD 3 resulted in an improvement in the performance and inflammatory responses of broilers. A reduction in the inflammatory response subsequent to the in ovo injection of 2.4 μg of 25OHD 3 may have led to an increase in broiler performance.

Effects of the in ovo injection of vitamin D 3 ( D 3 ) and 25-hydroxycholecalciferol ( 25OHD 3 ) on broiler embryo serum 25OHD 3 concentrations, hatchability, and hatchling somatic characteristics were determined. Eggs from a 35-wk-old commercial Ross 708 broiler breeder flock were set in a single-stage incubator with 11 treatments represented on each of 8 incubator tray levels (blocks). Each treatment group within a flat on each tray level contained 30 eggs. Control treatments were noninjected and diluent injected. Vitamin treatments were commercial diluent containing 0.6 μg D 3 , 0.6 μg 25OHD 3 , 0.6 μg D 3 + 0.6 μg 25OHD 3 , 1.2 μg D 3 , 1.2 μg 25OHD 3 , 1.2 μg D 3 + 1.2 μg 25OHD 3 , 2.4 μg D 3 , 2.4 μg 25OHD 3 , or 2.4 μg D 3 + 2.4 μg 25OHD 3 . At 432 h of incubation ( hoi ), 50-μL solution volumes were injected. Blood samples were collected at 462 hoi for serum 25OHD 3 analysis, and hatchability of injected live embryonated eggs ( HI ) was determined at 492 and 516 hoi. At 516 hoi, hatchling yolk-free BW and weights of the liver and yolk sac were determined. Percentage of yolk moisture and dry mater was calculated. At 492 and 516 hoi, HI did not differ between treatments. Embryos that received 1.2 μg or more of either vitamin D 3 source alone or in combination had higher serum 25OHD 3 concentrations than those that were injected with diluent alone or diluent containing 0.6 μg of D 3 . Hatchlings that received 1.2 or 2.4 μg of 25OHD 3 had higher percentage of yolk dry matter or lower percentage of yolk moisture levels than noninjected controls and those that received D 3 alone at any level. These results indicate that the in ovo injection of either vitamin D 3 source at levels equal to or higher than 1.2 μg resulted in serum 25OHD 3 concentrations that were higher than that of noninjected controls. In addition, the in ovo injection of 1.2 μg or higher of either vitamin D 3 source did not negatively affect broiler HI or chick quality.

Effects of dietary Original XPC (XPC) in commercial layer pullets challenged with the virulent, low passage R strain of Mycoplasma gallisepticum (R low MG) were investigated. Hy-Line W-36 pullets sourced from MG-clean breeders were fed a basal diet with or without (CON) XPC (1.25 kg/metric ton) from hatch until 12 wk of age (woa). At 8 and 10 woa, half of the birds in each dietary treatment were challenged with R low MG. Body weight was recorded at 3, 8, and 12 woa, and ovary, ceca, and bursa weights were recorded at 3 and 12 woa. Blood samples were taken immediately before the initial R low MG challenge at 8 woa and again at 12 woa to test for IgM and IgG antibody production against MG. All birds were evaluated for MG lesion scores at 12 woa. Regardless of challenge, inclusion of XPC in the diet did not significantly alter BW at 3 or 8 woa or relative organ weights at 3 or 12 woa. However, at 12 woa, BW of XPC-fed birds, regardless of challenge was significantly ( P = 0.0038) heavier than CON by 25.7 g. All birds tested negative for MG antibodies before the 8 woa challenge. Respective percentage serum plate agglutination and ELISA positive birds at 12 woa were 0 and 0% (CON, nonchallenged), 1.4 and 0% (XPC, nonchallenged), 100 and 47.2% (CON, challenged), and 100 and 50.0% (XPC, challenged). Diet did not significantly affect ELISA titers, but they were significantly ( P < 0.0001) increased due to challenge. Furthermore, lesion scores were significantly higher for R low MG-challenged birds ( P = 0.0012), and dietary treatment with XPC in challenged birds numerically reduced MG lesion scores from 0.278 to 0.194. In conclusion, although dietary XPC did not significantly alter the humoral immune response, antibody titer levels, or severity of MG lesions in layer pullets that were or were not challenged with R low MG, it led to an increase in their rate of growth through 12 woa.

Effects of the in ovo administration of vitamin D 3 ( D 3 ) and 25-hydroxyvitamin D 3 ( 25OHD 3 ) on broiler intestinal lesion incidence, performance and breast meat yield after a coccidiosis challenge were investigated. On each of 10 incubator tray levels, 10 Ross 708 broiler hatching eggs were randomly assigned to each of the following 5 in ovo injection treatments administrated at 18 d of incubation ( doi ): 1) noninjected; 2) diluent; diluent containing either 3) 2.4 μg D 3 (D 3 ), 4) 2.4 μg 25OHD 3 (25OHD 3 ), or 5) 2.4 μg D 3 + 2.4 μg 25OHD 3 (D 3 +25OHD 3 ). A 50 μL solution volume was injected into each egg using an Inovoject multi-egg injector. Four male chicks were randomly assigned to each of 80 battery cages in each of 2 rooms. Half of the treatment-replicate cages (8) in each room were challenged with a 20× live coccidial vaccine at 14 d of age ( doa ). One randomly selected bird from each of 4 treatment-replicate cages was scored for coccidiosis lesions before and 2 wk after challenge. Mean BW, BW gain ( BWG) , feed intake, and feed conversion ratio were determined for all birds from 0 to 14, 15 to 28, and 29 to 41 doa. Carcass weight, and the absolute and relative (% of carcass weight) weights of carcass parts were determined in 3 birds per treatment-replicate cage at 42 doa. Hatchability of live embryonated injected eggs and hatch residue were not affected by treatment. Across challenge treatment, birds in the 25OHD 3 treatment group experienced an increase in BWG between 29 and 41 doa when compared to the D 3 or diluent-injected birds. Furthermore, pectoralis major muscle percentage tended ( P = 0.059) to increase in birds belonging to the 25OHD 3 treatment in comparison to birds in the D 3 or diluent-injected treatments. These results indicate that regardless of challenge treatment, 2.4 μg of 25OHD 3 may increase the BWG and breast meat yield of birds relative to those that only received an injection of commercial diluent.